Ethical issues in clinical trials involving nanomedicine

被引：56

作者：

Resnik, David B. ^{[1
]}

Tinkle, Sally S. ^{[1
]}

机构：

[1] NIEHS, Cellular Organ & Syst Pathobiol Branch, Div Extramural Res & Training, NIH, Res Triangle Pk, NC 27709 USA

来源：

CONTEMPORARY CLINICAL TRIALS | 2007年 / 28卷 / 04期

关键词：

nanomedicine; nanotechnology; ethics; clinical trials;

D O I：

10.1016/j.cct.2006.11.001

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

Nanomedicine shows tremendous promise for improving medical diagnosis, treatment, and prevention, but it also raises a variety of ethical concerns. Because of the paucity of data on the physicochemical properties of nanoscale materials in biological systems, clinical trials of nanomedicine products present some unique challenges related to risk minimization, management and communication involving human subjects. Although these clinical trials do not raise any truly novel ethical issues, the rapid development of nanotechnology and its potentially profound social and environmental impacts, add a sense of urgency to the problems that arise. (c) 2006 Elsevier Inc. All rights reserved.

引用

页码：433 / 441

页数：9

共 45 条

[1]

AMDURE R, 1992, I REV BOARD MEMBER H

[2]

[Anonymous], 1986, ETHICS REGULATION CL

[3]

[Anonymous], 2005, ETH RES INV AN

[4] FALSE HOPES AND BEST DATA - CONSENT TO RESEARCH AND THE THERAPEUTIC MISCONCEPTION [J].